Aviva PLC Has $6.78 Million Stake in Incyte Co. (NASDAQ:INCY)

Aviva PLC lifted its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 1,324.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,179 shares of the biopharmaceutical company's stock after buying an additional 91,289 shares during the quarter. Aviva PLC owned about 0.05% of Incyte worth $6,781,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Quintet Private Bank Europe S.A. acquired a new position in Incyte in the fourth quarter valued at about $26,000. Global X Japan Co. Ltd. raised its position in shares of Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 230 shares during the period. R Squared Ltd bought a new position in Incyte during the 4th quarter worth approximately $30,000. Groupama Asset Managment grew its holdings in Incyte by 11.4% during the third quarter. Groupama Asset Managment now owns 59,597 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 6,105 shares during the period. Finally, Blue Trust Inc. increased its stake in Incyte by 124.6% in the fourth quarter. Blue Trust Inc. now owns 593 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 329 shares in the last quarter. 96.97% of the stock is owned by institutional investors.

Insider Activity at Incyte

In other Incyte news, EVP Sheila A. Denton sold 14,069 shares of the company's stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total value of $1,042,090.83. Following the transaction, the executive vice president now directly owns 25,848 shares of the company's stock, valued at $1,914,561.36. This represents a 35.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Steven H. Stein sold 12,352 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total value of $897,866.88. Following the transaction, the executive vice president now owns 66,967 shares in the company, valued at $4,867,831.23. The trade was a 15.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,827 shares of company stock worth $3,322,618. Insiders own 17.60% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Morgan Stanley decreased their price target on shares of Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday, March 24th. Guggenheim cut Incyte from a "buy" rating to a "neutral" rating and set a $92.00 target price for the company. in a research note on Tuesday, March 18th. UBS Group initiated coverage on Incyte in a research report on Tuesday, December 17th. They set a "neutral" rating and a $77.00 price target on the stock. Citigroup cut their price objective on Incyte from $97.00 to $88.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. Finally, William Blair cut Incyte from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Incyte presently has a consensus rating of "Hold" and a consensus price target of $74.88.

Incyte Stock Performance

NASDAQ:INCY traded up $1.25 on Monday, hitting $58.12. The company's stock had a trading volume of 217,658 shares, compared to its average volume of 2,372,739. Incyte Co. has a one year low of $50.35 and a one year high of $83.95. The firm has a market capitalization of $11.25 billion, a P/E ratio of 215.27, a price-to-earnings-growth ratio of 0.41 and a beta of 0.89. The stock has a fifty day moving average of $66.19 and a two-hundred day moving average of $69.63. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. Research analysts predict that Incyte Co. will post 4.86 earnings per share for the current year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.